Ariad Pharmaceuticals, Inc.

NASDAQ: ARIA
$23.99
+$0.00 (+0.0%)
Closing price February 17, 2017
The top analyst upgrades, downgrades and initiations on Tuesday include American Express, Goldman Sachs, Illumina, PayPal, Trivago and Williams Companies.
Jon C. Ogg
As the second week of the New Year is now underway, a few biotech companies made sizable runs to kick off the week.
Chris Lange
24/7 Wall St. has identified several immediate winners from a Donald Trump presidency. These are all surging higher.
Jon C. Ogg
Ariad Pharmaceuticals said it had a loss in the most recent quarter. However, incredibly positive growth for its flagship drug pulled this company through.
Chris Lange
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
Jon C. Ogg
Shares of Ariad Pharmaceuticals saw a modest gain early Monday after the company announced a recent FDA decision.
Chris Lange
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Ariad Pharmaceuticals, AT&T, Chesapeake Energy, Hain Celestial, Nike and Visa.
Jon C. Ogg
Ariad Pharmaceuticals shares were down handily on Monday after JPMorgan downgraded the stock. Also Senator Sanders recently asked about the pricing of its blood cancer drug Iclusig.
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Monday morning include Ariad Pharmaceuticals, Comcast, ConEd, Electronic Arts, Kinder Morgan, 3M and Time Warner.
Jon C. Ogg
A new research report from Jefferies notes that when price momentum has been as bad as it has been recently, it tends to rebound in a big way.
Lee Jackson
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
Chris Lange
The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to June 7 in Chicago.
Chris Lange
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
Chris Lange
Source: ThinkstockThe solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and other forms of deals in the sector. This most recent...
Chris Lange, Jon C. Ogg
In a new report, Stifel sees two biotech stocks with near-term catalysts that could make takeover candidates soon.
Lee Jackson